Fingerprint
Dive into the research topics of 'Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: Results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically